Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

stapokibart

A recombinant humanized monoclonal antibody directed against the alpha chain of the interleukin-4 receptor (IL-4RA; IL-4R alpha), with potential anti-inflammatory and immunomodulatory activities. Upon administration, stapokibart selectively binds to IL-4RA. This disrupts IL-4/IL-13 signaling and prevents the activation of downstream pathways that mediate type 2 inflammation. IL-4 and IL-13 receptors are present on the surface of numerous cells involved in the pathophysiology of type-2 helper T-cell (Th2) allergic responses, including B lymphocytes, eosinophils, dendritic cells (DCs), monocytes, macrophages, basophils, keratinocytes, bronchial epithelial cells, endothelial cells, fibroblasts, and airway smooth muscle cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-IL-4 receptor alpha monoclonal antibody CM310
anti-IL-4RA monoclonal antibody CM310
anti-interleukin-4 receptor subunit alpha monoclonal antibody CM310
Code name:CM 310
CM-310
CM310
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search